Agonism, Antagonism, and Efficacy
Agonism, antagonism, and efficacy are the core concepts that describe what a drug does once it has bound to its receptor. Affinity governs whether a ligand binds; efficacy governs what happens next — whether binding activates the receptor (agonism), partially activates it (partial agonism), blocks the action of other ligands (antagonism), or suppresses constitutive activity (inverse agonism). This area collects the vocabulary and quantitative framework pharmacology uses to classify drug action at receptors.
Definition
Agonism is the property of a ligand that activates a receptor to produce a response; antagonism is the property of a ligand that occupies or modifies a receptor without activating it, thereby reducing the effect of agonists; and efficacy is the parameter that quantifies the ability of a bound ligand to change receptor behaviour, distinguishing agonists (positive efficacy) from neutral antagonists (zero efficacy) and inverse agonists (negative efficacy).
Scope
The area orients the reader across the spectrum of receptor-mediated drug action: full and partial agonists, competitive and other antagonists, inverse agonists acting on constitutively active receptors, and the modern recognition that a single receptor can be driven toward different signalling outcomes (biased agonism). It is a conceptual and methodological reference within pharmacodynamics, not a guide to drug selection or dosing.
Sub-topics
Core questions
- What distinguishes affinity from efficacy in describing drug-receptor interaction?
- How are agonists, antagonists, and inverse agonists classified along a single efficacy continuum?
- How does the operational model relate observed response to the underlying agonist concentration-effect relationship?
- Why can the same receptor produce different responses depending on which ligand activates it?
Key concepts
- Affinity versus efficacy
- Intrinsic activity
- Full agonist
- Partial agonist
- Competitive antagonist
- Inverse agonist
- Constitutive (basal) receptor activity
- Biased agonism / functional selectivity
- Spare receptors and receptor reserve
Key theories
- Operational (Black-Leff) model of agonism
- Relates observed tissue response to agonist concentration through an affinity constant and an efficacy term (the transducer ratio), separating drug-specific properties from system-dependent factors and providing a quantitative basis for comparing agonists.
- Affinity-efficacy distinction
- Treats binding (affinity) and the consequence of binding (efficacy) as logically separate parameters, allowing ligands of similar affinity to differ widely in the response they produce.
Mechanisms
Drug action at a receptor is conventionally decomposed into two steps: binding, governed by affinity, and the change in receptor state that binding causes, governed by efficacy. A full agonist produces the maximal response a system can give; a partial agonist produces a submaximal response even at full occupancy; a neutral antagonist binds without changing receptor activity and blocks agonists; and an inverse agonist reduces receptor signalling below its unliganded (constitutive) baseline. The operational model of Black and Leff formalises how the observed response relates to occupancy through an efficacy term, while later work recognised that ligands can stabilise distinct active conformations, so that efficacy is not a single number but can differ across the several pathways a receptor couples to.
Clinical relevance
These concepts underlie how the actions of large classes of medicines are described — receptor agonists, blockers, and partial agonists appear throughout pharmacology — and they explain observations such as why a partial agonist can behave as a functional antagonist in the presence of a full agonist. The area is reference material for understanding drug classification and mechanism; it describes how drug action is conceptualised and is not a basis for individual prescribing or dosing decisions.
Evidence & guidelines
The terminology in this area follows the International Union of Basic and Clinical Pharmacology (IUPHAR) committee recommendations on receptor nomenclature and quantitative pharmacology, which define agonist, antagonist, efficacy, and related symbols for consistent use across the literature.
History
The vocabulary of agonism and antagonism grew out of early twentieth-century receptor theory and occupancy models, was sharpened by the affinity-efficacy distinction in the mid-century, and was placed on an explicit quantitative footing by the operational model of Black and Leff in 1983. The discovery of constitutive receptor activity and inverse agonism, and later of ligand-biased signalling, progressively expanded the framework beyond a simple agonist-antagonist dichotomy.
Key figures
- James W. Black
- Paul Leff
- Terry Kenakin
- David Colquhoun
- Richard R. Neubig
Related topics
Seminal works
- black-leff-1983
- colquhoun-1998
- neubig-2003
Frequently asked questions
- What is the difference between affinity and efficacy?
- Affinity describes how tightly a ligand binds its receptor, while efficacy describes what the bound ligand does to the receptor's activity. Two drugs can bind equally well yet differ in efficacy, so one acts as an agonist and the other as an antagonist.
- Is an antagonist the same as an inverse agonist?
- No. A neutral antagonist binds without changing receptor activity and simply blocks agonists, whereas an inverse agonist actively reduces receptor signalling below its baseline level, which matters only when the receptor has constitutive activity.